ANTABIO
Desconocido
sbli-ant3310: A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critic...
ANTABIO
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2022-ACCELERATOR-01
Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria are an increasingly serious healthcare threat, exacerbated...
2023-01-20 - 2026-04-30 | Financiado
2023-01-20 - 2026-04-30 | Financiado
Train2Target: An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics Targeting function...
ANTABIO
participó en un
H2020:
H2020-MSCA-ITN-2016
Train2Target is a multidisciplinary European Training Network built to address the challenge of the discovery of alternative antimicrobials....
2016-08-31 - 2020-12-31 | Financiado
2016-08-31 - 2020-12-31 | Financiado
* No se disponen de datos de la empresa actual.